Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

The perioperative administration of selective cyclooxygenase-2 (COX-2)-inhibitors to avoid postoperative pain is an attractive option: they show favorable gastro-intestinal tolerability, lack inhibition of blood coagulation, and carry a low risk of asthmatic attacks. The purpose of this study was to determine the cerebrospinal fluid (CSF), plasma, and tissue pharmacokinetics of orally administered etoricoxib and to compare it with effect data, i.e., COX-2-inhibition in patients after hip surgery. The study was performed in a blinded, randomized, parallel group design. A total of 12 adult patients were included who received 120 mg etoricoxib (n = 8) or placebo (n = 4) on day 1 post-surgery. Samples from plasma, CSF, and tissue exudates were collected over a period of 24 h post-dosing and analyzed for etoricoxib and prostaglandin E(2) (PGE(2)) using liquid chromatography-tandem mass spectrometry and immuno-assay techniques. CSF area under the curve (AUC) [AUCs((O-24h))] for etoricoxib amounted to about 5% of the total AUC in plasma (range: 2-7%). Individual CSF lag times with respect to (50%) peak plasma concentration were </=2 h in all but one case (median: 1 h). PGE(2) production in tissue was significantly blocked by the COX-2 inhibitor starting with the appearance of etoricoxib in tissue and lasting for the whole observation period of 24 h (P < 0.01). In conclusion, etoricoxib reaches the CSF and site of surgery at effective concentrations and reduces PGE(2) production at the presumed site of action.

RCT Entities:   Population Interventions Outcomes

Introduction

Surgical trauma induces cyclooxygenase-2 (COX-2) upregulation and subsequent synthesis of prostaglandins locally (Lipsky et al. 1998) and in the central nervous system (CNS; Dolan et al. 2003). This leads to peripheral and central hyperalgesia (Woolf and Chong 1993; Reinold et al. 2005). Selective COX-2 inhibitors appear to block both peripheral and central hyperalgesia, but have little or no effect on platelet aggregation and asthma. These characteristics make them attractive candidates for perioperative use (Viola et al. 2007; Schwartz et al. 2008). Etoricoxib (a new selective COX-2 inhibitor available in many countries) has been reported to reduce postoperative pain after orthopedic surgery (Toivonen et al. 2007; Turan et al. 2008). When administered postoperatively to patients who had undergone hip replacement, etoricoxib provided analgesia similar to controlled release naproxen and superior to placebo (Rasmussen et al. 2005).

Prostaglandin E2 (PGE2) is the predominant eicosanoid released in damaged tissue (Samad et al. 2002). Animal data demonstrate an increase in spinal PGE2 after peripheral injury (Dirig and Yaksh 1999). Spinal administration of a COX-2 inhibitor in an animal inflammatory model decreased peripheral inflammation-induced central PGE2 concentrations and mechanical hyperalgesia (Woolf and Chong 1993; Samad et al. 2001; Reinold et al. 2005). In rats, similar results were demonstrated in a post-surgical pain model (Kroin et al. 2002, 2004). It seems attractive to propose that COX-2 inhibitors act equally in humans due to a similar cerebrospinal fluid (CSF) and tissue drug uptake compared to animals. However, interspecies differences in blood brain barrier and different degrees of protein binding may alter the drug uptake at these sites of action (Shen et al. 2004; Summerfield et al. 2006). Therefore, clinical investigations in humans are needed before defining the proper dosing of etoricoxib in the perioperative setting. There are only a few recent studies characterizing plasma and CSF pharmacokinetics of COX-2 inhibitors (celecoxib, rofecoxib, and valdecoxib) in humans (Buvanendran et al. 2005; Dembo et al. 2005). A recent pharmacodynamic study with rofecoxib in humans to evaluate CSF interleukin 6 and PGE2 concentrations following orthopedic surgery demonstrated increased levels of these mediators after surgery (Buvanendran et al. 2006). CSF PGE2 concentrations were positively correlated with postoperative pain and the content of PGE2 in tissue exudates correlated with the functional outcome (Buvanendran et al. 2006). Since rofecoxib and valdecoxib have been removed from the market, human data for the remaining COX-2 inhibitors, such as etoricoxib, are missing.

We set out to study the pharmacokinetics of etoricoxib in plasma, CSF, and tissue exudate in order to optimize the dosing and therapeutic benefits of this drug. In this pilot study, we characterized in patients the time course of etoricoxib appearance in CSF and damaged tissue (tissue exudates from surgical site) and determined its effect on PGE2 production at these sites of analgesic action.

Methods

After approval from the German authorities and the Institutional Ethics Review Board, 12 male and female patients (age 55–80 years) with osteoarthritis undergoing elective primary single hip arthroplasty were consented. All patients were recruited at the Department of Orthopedics, HELIOS Klinikum Berlin–Buch, Germany. The clinical trial is registered at EudraCT (#2005-003854-80) and at ClinicalTrails.gov (#NCT00746720). The study was conducted according to the Declaration of Helsinki on biomedical research involving human subjects (Somerset West amendment). All patients gave their informed consent prior to their inclusion in the study. One patient dropped out due to detectable etoricoxib plasma concentrations before receiving the first dose; another patient was unblinded 2 days after drug administration due to an adverse event (hemolytic anemia and hemoglobin decrease) which was unlikely related to the study drug. This patient received diclofenac at day 3 post-surgery as a routine medication and was found positive for diclofenac antibodies.

Patients and study design

Exclusion criteria were: renal insufficiency (serum creatinine >1.5 mg/dL), recent major trauma or systemic infection (within 3 months), history of usage of corticosteroid medication, or chronic opioids (within 3 months), conditions likely to affect prostaglandin levels and conditions contraindicating spinal anesthesia. In addition, patients were excluded if they had the following characteristics: hypersensitivity to any component of the study medication; uncontrolled hypertension defined as systolic blood pressure >160 mm Hg and diastolic pressure >90 mm Hg during rest at two repeated measurements; congestive heart failure (NYHA II–IV); cerebrovascular disease; established ischemic heart disease (including patients who had recently undergone coronary artery bypass graft surgery or angioplasty); elevated liver function enzymes (threefold above normal range); patients who had developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic edema, or urticaria following the administration of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs; pregnancy and lactation; patients with active peptic ulcerations or active gastro-intestinal bleeding; and inflammatory bowel disease.

Preoperative demographic data were collected and all preoperative medications including dose, route, and duration were recorded. Pain scores were assessed using a numerical rating scale (11 point category scale: 0 = no pain, 10 = worst possible pain; Downie et al. 1978). Thus, the global (overall) pain and the specific pain for the operative hip at rest and passive movement were obtained before and after surgery.

The study was restricted to a sampling period of 24 h due to safety reasons (overall sampling volume for CSF and plasma). Patients received the spinal anesthetic bupivacaine 0.5% (7.5–10 mg) via an intrathecal (IT) catheter placed at the lumbar 3–4 or 4–5 interspace. They were maintained at normothermia in the operating room by supporting means, including warmed intravenous fluids. Postoperatively, 0.01% bupivacaine was infused intrathecally at a continuous rate superimposed by patient controlled IT boluses. Initial basal infusion rate was 4 mL/h with patient controlled boluses of up to 1 mL q 10 min and a 4-h lockout of 40 mL. The patients were allowed to titrate intrathecal requirements for analgesia using a previously applied analgesic efficacy protocol (Buvanendran et al. 2003). Intravenous morphine (or equivalent opioid) was given at a dose of 1–2 mg for breakthrough pain. Total drug consumption was recorded. If patients had a temperature >39°C, oral acetaminophen 1.0 g was administered after contact with one of the investigators. A standardized surgical technique of non-cemented hip arthroplasty was used for all patients.

As the study was focused on the PK data from three matrixes during absorption period, only four patients served as placebo controls. On postoperative day 1, eight patients received oral etoricoxib 120 mg at 7.00 am and four patients received a placebo. The study was blinded to patients and the investigators, but not to the analytical department. Blood (3 mL) and CSF samples (0.5 mL) were collected before and at the following time points after drug administration: 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, and 24 h (eight time points). The initial 1 ml of each CSF sample was discarded to account for dead space in the catheter and to avoid possible dilution artifacts regarding the intrathecally applied bupivacaine. The postoperative analgesic IT solution was administered to provide continuous analgesia for the patients between sampling time points.

Tissue exudates (hip drain) were collected at 0.0 (before), 1.0, 3.0, 8.0, 12.0, and 24 h after drug administration. One hour before the scheduled collection time, the Redon drain system (B. Braun AG, Melsungen, Germany) was emptied and the exudate was collected over the next 60 min (additional sampling times at 2.0, 7.0, 11.0, and 23 h post-medication). Drain fluids were centrifuged and the supernatant frozen at −30°C and sent for analysis.

Pharmacokinetic analysis

Following oral etoricoxib, pharmacokinetic parameters were determined in plasma, tissue exudate, and CSF in each subject using a liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analytical method was adapted from published work on plasma using phenazone as an internal standard (Brautigam et al. 2003). The detection was performed on API 4000 (Applied Biosystems, Langen, Germany) and determination of the limits of quantification (LOQ) for etoricoxib plasma, CSF, and tissue exudates were carried out according to the Food and Drug Administration (FDA) guidelines (US Department of Health and Human Services, 2001). The LOQ for etoricoxib was 0.2 ng/mL in all three matrixes. The analytical method was validated over the concentration range 0.2–200 ng/mL. The area under the curve (AUC) [ng·h/mL] from 0 to 24 h was calculated for both CSF and plasma data using the linear trapezoidal method. The fraction of plasma etoricoxib in the CSF was calculated from the ratio of AUCCSF to AUCplasma at each sampling time.

PGE2 analysis from tissue samples was performed using enzyme linked immunoassay kits (Cayman Chemical, MI, USA). The LOQ for PGE2 was 15 pg/mL. CSF samples were analyzed for PGE2 using LC-MS/MS methods, which were developed in this study using a stable isotope of prostaglandin D2–d4. The solid phase extraction method and the LC-MS/MS conditions were adjusted to our API 4000 system using previous publications (Nithipatikom et al. 2003; Schmidt et al. 2005). The lower LOQ was 25 pg/mL and the upper LOQ was 200 pg/mL according to FDA guidelines (US Department of Health and Human Services 2001). The PGE2 concentrations at the central (CSF) and peripheral (tissue exudate) sites over time were compared between the study groups.

Secondary parameters

Pain scores at rest and passive movement of the operated hip were assessed at 4.0, 8.0, 12, 24, 26, 32, and 48 h time points after study drug administration. The total IT medication consumption, the number of patient activated requests, delivered boluses, and time of requests were documented. Tympanic temperature was monitored at the preoperative visit and at each blood and CSF measurement time points.

Hematology comprising a complete blood count with counts of leukocytes and platelets was obtained preoperatively and postoperatively as per routine standard care. Blood products transfused in the perioperative phase were recorded. In addition, coagulation parameters were measured and recorded (preoperatively and postoperatively). Patients rated their sleep disturbance due to pain at 24 h after surgery (0 = no sleep disturbance to 10 = greatest sleep disturbance; Buvanendran et al. 2003).

Statistical analysis and sample size estimation

Demographic and other univariate data were analyzed using t tests, χ 2 tests, and Fisher’s exact tests, the Mantel–Haenszel test, or the Mann–Whitney U-test, contingent on the scale and distributional characteristics of the variables, and applying the Bonferroni step-down correction method to adjust for multiple comparisons. Unless otherwise indicated, descriptive statistics are reported as mean and standard deviation (SD) for continuous normally distributed variables, or as median and interquartile range for ordinal or non-normally distributed variables, while dichotomous variables are reported using counts and/or percentages. Outcomes with measures at multiple time points were analyzed using repeated-measures analysis of variance with an auto-regressive covariance structure to account for the correlated nature of individual patient contributions.

Initial pilot data obtained with rofecoxib indicated a significant reduction in CSF PGE2 concentrations, but with variability differing between the two groups (Buvanendran et al. 2006). In an effort to address this issue in our actual study, the treatment group was oversampled at a rate of 2 to 1 as compared to the placebo group. Assuming a threefold reduction in CSF PGE2 concentrations with a SD of 60 pg/mL for the treatment group and 40 pg/mL for the placebo, a total sample size of 12, with eight treatment subjects and four placebo subjects, will provide 84% power to detect a significant difference for a two-sided t test [data for sample size estimation were taken from (Buvanendran et al. 2006)]. Relationships between variables were evaluated using the Pearson product-moment correlation. P < 0.05 was used to determine statistical significance. All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, NC, USA).

Results

An analysis of the demographic variables for the two groups of patients shown in Table 1 demonstrates that there were no significant differences. The duration of surgery and blood loss for the two groups was also not different. For the active treatment group, hematological parameters such as hemoglobin were slightly lower in the postoperative period compared to preoperative values. There were no meaningful differences in postoperative pain and opioid consumption, neither in the pain scores at rest globally and also during movement between the two groups of patients. During the 48 h postoperative period, the amount of intrathecal drug (IT boluses of bupivacaine) administered, titrated to provide postoperative analgesia, did not differ between the two groups. Similarly, there was no difference in the use of additional analgesics, but the study was not designed to detect such differences as both groups received standard IT and parenteral pain medication at this state post-surgery.

Table 1

Demographic characteristics of the patients

	Placebo (n = 3)a	Etoricoxib (n = 8)	P value
	Mean (SD)	Mean (SD)
Age (yr)	67.4 (2.4)	72.1 (5.4)	0.1963
Weight (kg)	88.5 (16.3)	77.4 (8.9)	0.2031
Height (cm)	171 (9)	163 (8)	0.2442
Sex (counts)			0.3869b
Female/male	1/2	5/3
Race (counts)			ND
Caucasian	3 (100%)	8 (100%)
Duration of surgery (min)	56 (19)	39 (6)	0.2609
Intra-OP BL (mL)	300 (0)c	440 (114)c	0.0516

Values are mean (standard deviation) unless otherwise indicated

SD standard deviation, Intra-OP BL blood loss during surgery, ND not done (statistic cannot be computed)

aOne patient in the placebo group dropped out due to clinical reasons

bChi-square test, due to low counts P value may be biased

cDue to missing values n = 2/n = 5 in the placebo/etoricoxib group

Prostaglandin E2 concentrations

We observed a significant difference in the PGE2 concentration in the tissue exudate between the etoricoxib and placebo group despite the small number of patients in the placebo group (Fig. 1 and Table 2). This difference became significant in the samples retrieved 5 h after medication. It lasted 18 h till the end of the observation period. There was a time lag between exudate production and sample recovery from the Redon drain. The material sampled at, e.g., 5 h was produced about 2 h after medication. Altogether, we found a negative correlation (R = −0.7; P = 0.02) between the concentration of etoricoxib and that of PGE2 in the tissue exudates.

Fig. 1

Time course of etoricoxib and prostaglandin E2 (PGE2) concentrations in tissue exudates. PGE2 concentrations are shown as differences to baseline values. Sample times are midpoints of collection intervals (means ± SEM; placebo group n = 3; etoricoxib group n = 8). Absolute PGE2 concentrations and statistical data are given in Table 1

Table 2

Statistical summary for PGE2 concentrations [ng/mL] in tissue exudate

	Placebo (n = 3)b	Etoricoxib (n = 8)	P value
	Mean (SD)	Mean (SD)
Overall difference for all values
PGE2 Hip (n = 88)	33.7 (22.7)	11.9 (10.2)	<.0001
Regression model
PGE2 Hip
Interaction			<.0001a
Main effect			0.0073a
Time points contrastsc
Pre	15.4 (14.6)	7.7 (5.4)	0.3158
−0.5 h	21.2 (5.0)	15.1 (9.1)	0.4406
0.5 h	20.1 (3.5)	18.1 (8.8)	0.4103
1.5 h	27.8 (5.5)	24.4 (10.5)	0.2002
2.5 h	27.4 (10.9)	20.9 (16.1)	0.4170
5.0 h	53.9 (24.5)	16.9 (13.6)	<.0001a
7.5 h	57.0 (39.8)	12.1 (9.3)	<.0001a
9.5 h	50.4 (27.7)	7.9 (6.0)	<.0001a
11.5 h	41.1 (24.1)	6.4 (5.1)	0.0001a
17.5 h	27.9 (20.1)	6.2 (6.2)	0.0061a
23.5 h	24.2 (23.0)	2.3 (0.7)	0.0141a

All

aStatistically significant at alpha = 0.05

bOne patient in the placebo group dropped out due to clinical reasons

cTime points are midpoints of collection intervals

PGE2 = prostaglandin E2; SD = standard deviation

PGE2 values were modeled using repeated measures analysis of variance. Maximum likelihood parameter estimates were generated using an auto-regressive mixture model.

The CSF PGE2 concentrations were below the quantification limit of the LC-MS/MS method in most cases. Therefore, AUCs could not be calculated and group analysis was not performed for this parameter.

Etoricoxib concentrations

A summary of the pharmacokinetic data is given in Table 3. The 24-h concentration-time curves of etoricoxib in plasma, CSF, and tissue exudate are shown in Fig. 2 with semilogarithmic presentation. Data with linear scaling are given in Figs. 1 and 3a, respectively. The drug concentration in the CSF lagged behind that of plasma. In plasma, etoricoxib concentrations peaked at 1 h on average (see Fig. 2). At that time, CSF concentrations were measurable, but reached only about a third (34%) of the peak concentration which was observed at 8 h (Fig. 3a and Table 3). In both compartments, a plateau was reached after about 2 h (compare Fig. 2). The CSF/plasma concentration ratio of the drug in absolute terms was 0.016 at 1 h and increased to 0.030 and 0.057 at 2 and 4 h, respectively. On time average, the maximum CSF/plasma ratio (0.063) occurred at 8 h. Individual maximum concentration ratios were observed to be 7.3% (±2.1) between 3 and 12 h post-drug administration. The mean CSF/plasma ratio with respect to AUC0–24h was 4.4% (see Table 3 and Fig. 3b).

Table 3

Pharmacokinetic parameters of etoricoxib comparing cerebrospinal fluid (CSF) and plasma data

	Plasma		CSF
	n = 8 (all patients)	n = 5a	n = 5a
AUC0–24h [h × ng/mL]b	22,197 (5,780)	22,587 (5,759)	955 (354)
t max [h]c	3 (1–24)	4 (1–24)	8 (2–12)
c max [ng/mL]b	1735.1 (1206.4)	1437.6 (533.8)	68.4 (30.6)
CSF/plasma ratio AUC0–24h [%]d		4.4 (2–7)
t max [h] for CSF/plasma conc. ratioc		8 (3–12)
CSF/plasma conc. ratio [%] at t maxb		6.3 (2.0)
Max. CSF/plasma conc. ratio [%]e		7.3 (2.1)

SD standard deviation, conc. concentration

aSubgroup analysis without data from three patients due to incomplete CSF samples

bMean (± SD)

cMedian (range)

dIndividual CSF/plasma ratios were calculated using AUC0–24h; mean (range) data are given in percentage values

eMax. CSF/plasma ratios were calculated using individual maximal concentration ratios (mean ± SD) data are given in percentage values

Fig. 2

Etoricoxib concentrations in three different matrixes (plasma, cerebrospinal fluid [CSF] and tissue exudates, semi logarithmical presentation). Not quantifiable concentrations were set to the LOQ of 0.2 ng/mL (means ± SEM; n = 8). Tissue exudate sampling times are midpoints of collection intervals. Note: it took about 2 h until tissue exudate reached the end of the Redon drain (sample recovery)

Fig. 3

a Plasma and cerebrospinal fluid (CSF) concentrations after administration of 120 mg etoricoxib orally to eight patients (linear presentation, means ± SEM). b Corresponding time course of individual and mean CSF/plasma concentration ratios indicating the relative etoricoxib penetration into the CSF; mean data (black) are based on complete data sets from five patients only, but all individual patient data (n = 8) are presented (patients data, gray); descriptive data are given in Table 3

The median CSF lag time with respect to 50% of the peak concentration in plasma was 0.5 (1 if patient R09 is included) h, range 0-2 (7 if R09 included) h. One patient (R09) showed an extended lag time (7 h) which may be due to a second fractionate absorption resulting in a higher CSF peak concentration (108 ng/mL) at 8 h post-medication (see Table 4).

Table 4

Individual lag times [h] of etoricoxib for tissue exudate and cerebrospinal fluid (CSF)

Patient #	R01	R02	R05	R06	R07	R09	R10	R12	MEDIAN	MEAN
Plasma vs. Tissue exudate	4	4	ND	1.5	6.5	ND	3	ND	4	3.8
Plasma vs. CSF	1	2	(2)	0	(3)	7	(0)	0	1	2

ND sample not done, () invalid data due to missing values

Lag times were calculated with respect to 50% of peak concentrations

Tissue exudate concentrations for etoricoxib appeared to lag behind plasma and CSF with virtually no drug detected at 2.5 h (Figs. 1 and 2). The virtual lag time (without correction for the delay of sampling) for 50% peak concentration ranged between 1.5 and 6.5 h (median 4 h; see Table 4).

Discussion

This is the first study in humans to characterize the pharmacokinetics of the COX-2 inhibitor etoricoxib in the CSF, plasma, and tissue exudate simultaneously and in conjunction with effect data from the putative sites of action. The main finding of this pilot study is that plasma etoricoxib enters the CSF with a lag time of about 1 h and reaches a CSF/plasma concentration ratio of approximately 5%. At the site of surgery, we observed that PGE2 production was still high 1 day after surgery. In the placebo group, it increased further whereas it decreased significantly in the treatment group beginning with the appearance of etoricoxib in the wound fluid.

It was not the aim of this study to investigate the analgesic effect of etoricoxib in patients. This is obvious from the fact that the patients received complete routine analgesic treatment and that etoricoxib was administered 24 h after surgery, i.e., at a time when postoperative pain has subsided considerably and body functions have recovered. We observed no perioperative side effects related to the administration of etoricoxib. Signs of higher blood loss in the etoricoxib compared to the placebo group (see Table 1) were not caused by the drug, since they occurred before drug administration.

Our pharmacokinetic results are comparable to those seen in healthy volunteers, but indicate differences as well. Fast absorption and slow elimination is seen in our elderly postoperative patients, too, but the time to peak is more variable. Consistent with data published previously, a twin-peak pattern was observed in the plasma concentration–time curve of etoricoxib after administered orally to healthy subjects (Dallob et al. 2003; Agrawal et al. 2003a). Possible mechanisms for secondary peaks include biphasic dissolution or fractionated gastric emptying, and presence of two different absorption sites or enterohepatic recycling. All may be pertinent to our results.

In addition, we could show that a fast transfer of effective concentrations of etoricoxib into the CNS fluid and into the tissue exudates occurs. Indeed, meaningful (COX-2 inhibitory) CSF concentrations were reached within 2 h in nearly all patients. In absolute terms, the concentration in CSF fluid amounted to about a 1/20 of that seen at corresponding times in plasma (AUC0–24h and max. concentration ratios; Table 3 and Fig. 3b). The maximum etoricoxib CSF/plasma ratio (6%) occurred at 8 h. Similar ratios were seen with valdecoxib (4%) and celecoxib (1%) at 6 h after drug administration. The ratio is reported somewhat higher for rofecoxib (15–20%) with a corresponding lag time (Buvanendran et al. 2005; Dembo et al. 2005). The (time averaged) maximum CSF concentration was nearly 70 ng/mL for etoricoxib (Table 3), which exceeds the concentrations found in CSF for rofecoxib (40–60 ng/mL), valdecoxib (25 ng/mL), and celecoxib (2 ng/mL) after an oral dose for acute pain (Buvanendran et al. 2005; Dembo et al. 2005). This reflects the higher dose of etoricoxib (120 mg), as compared to rofecoxib (50 mg) and valdecoxib (40 mg) and the low bioavailability of celecoxib (20–60% at 200 mg; Brune and Hinz 2004; Hinz et al. 2007). CSF fluid is almost free of plasma proteins, and etoricoxib (as well as other COX-2 inhibitors), being highly bound (92%) to plasma proteins (Agrawal et al. 2003b), should reach concentrations in CSF similar to the free fraction in plasma. It is commonly accepted that uptake into the CNS is restricted to the unbound plasma fraction (Wilkinson 1983). We estimated the CSF/plasma ratio of the unbound fractions (CSF/Pu) at equilibrium (2–24 h). It was about 0.56 (SD ± 0.24). A similar brain/blood ratio for etoricoxib was reported in animals (0.66; SD ± 0.04) (Summerfield et al. 2006). Both estimates hint at a comparable CNS transfer rate of etoricoxib in man and rats.

CSF/Pu ratios for rofecoxib, valdecoxib, and celecoxib were reported before. The estimates range between 1.5 and 1.7 (Dembo et al. 2005). These data, clearly above 1.0, suggest an accumulation of these more lipophilic drugs in the CSF (Shen et al. 2004). The data quoted here were derived, however, in an unusual study. The volunteers received therapeutic doses of all three drugs at the same time. Therefore, complex interactions appear possible (Dembo et al. 2005).

The CSF concentrations of etoricoxib observed can be related to those which are required for 50% of COX-2 inhibition (IC50). Different IC50 values for several COX-2 inhibitors are reported. Most derive from in vitro assays including the original whole blood assay introduced by Patrignani (Patrignani et al. 1994). In this version of the assay, drug is added to human blood in vitro and the IC50 values defined. The published in vitro IC50 data for etoricoxib are lower than ex vivo results. In vitro data vary considerably from 0.26 to 0.5 µM for etoricoxib, from 0.19 to 0.93 µM for celecoxib, or from 0.1 to 0.65 µM for valdecoxib (Tacconelli et al. 2002; Gierse et al. 2005; Esser et al. 2005; Ushiyama et al. 2008). Data from ex vivo whole blood assays are limited or missing in order to compare between different COX-2 inhibitors. In this version of the assay, the drugs are given to volunteers and the COX-2 inhibition will be measured in blood containing the drug (Patrignani et al. 1994; Panara et al. 1998). In a recent study, using the ex vivo whole blood assay, Dallob determined the IC50 to be 1 µM (about 360 ng/mL) after a single dose of 120 mg etoricoxib (Dallob et al. 2003).

In our patients, meaningful (probably effective) concentrations of etoricoxib (>360 ng/mL) appeared during the first hour in plasma applying the conservative ex vivo IC50 data from Dallob et al. (Dallob et al. 2003). We observed comparable concentrations [free fraction 8% (Agrawal et al. 2003b)] of etoricoxib in the CSF (>29 ng/mL; >0,08 μM) 1 h later. This CNS lag time compares favorably with the onset of antipyretic action of etoricoxib at about 2 h post-dose in monkeys (Riendeau et al. 2001). Former studies in patients have shown that etoricoxib interferes with surgical pain within the first 2 h after administration (Clarke et al. 2009). In contrast to this observation are those published by Smirnov et al. (Smirnov et al. 2008). These authors investigated the effect of etoricoxib after thyroid surgery and found that it was not analgesic before 6 h after surgery. The difference may be explained by the fact that patients with thyroid dysfunction do not suffer from pain before surgery. Consequently, only surgery will induce COX-2 in the central nervous system de novo which, according to our knowledge, should take a few hours. That would explain the delayed onset despite probably fast absorption of etoricoxib in these patients.

A former investigation employing rofecoxib demonstrated that PGE2 concentrations in the CSF started to decline shortly after drug administration (Buvanendran et al. 2006). In contrast to this previous study, we sampled CNS fluid not directly following surgery, but 24 h thereafter. We found only low PGE2 concentrations (at the quantification limit) in CSF of treated and not-treated patients. These low concentrations appeared to decrease further in several patients on etoricoxib at or below the detection limit of our assay. Therefore, these data were not shown.

However, we observed increasing PGE2 concentrations at the site of surgery in the placebo group. Obviously, COX-2 was already induced following surgery at the day before. Consequently, we could observe an immediate action of etoricoxib when entering the inflamed tissue. Similar effects have been reported for rofecoxib, but without simultaneous sampling of PGE2 and drug concentration data at the wound site (Buvanendran et al. 2005, 2006). It should be kept in mind that the appearance and persistence of etoricoxib concentrations sufficient to interfere with PGE2 production may be instrumental for achieving inhibition of heterotopic ossification which has been shown for several drugs, including COX-2 selective inhibitors, but not yet for etoricoxib (Sodemann et al. 1990; Barthel et al. 2002; Buvanendran et al. 2007).

In conclusion, our pilot study supports the contention that the selective COX-2 inhibitor etoricoxib may be suitable for perioperative treatment in patients who are not at high risk for cardiovascular conditions. Indeed, we found that etoricoxib reaches meaningful CSF and wound fluid concentrations shortly after administration. Following the appearance of effective concentrations in these compartments, inhibition of prostaglandin production was observed. It appears plausible that this goes along with antihyperalgesia. Based on the results presented, it is planned to investigate the perioperative application of etoricoxib in a further study aimed at defining the analgesic effectiveness of etoricoxib under these conditions. The drug will be given before surgery and the postoperative pharmacokinetics and analgesic effects monitored thereafter.